New Teva CEO Brings Experience And This Secret Weapon
Teva Pharmaceutical Industries Ltd.'s newly appointed CEO, Kare Schultz, brings turnaround experience as the drugmaker faces challenges including generic drug pricing pressure in the U.S. and a substantial debt load.
"We think Mr. Schultz's experience leading financial and restructuring initiatives at global pharmaceutical and healthcare companies could help unlock value for TEVA shares," wrote Cantor Fitzgerald & Co. analyst Louise Chen in a note on Monday, Sept. 11.
Oppenheimer & Co. Inc. analyst Derek Archila wrote that while he views the news positively, Schultz "will be entering the company at a turbulent time, given: (1) continued pricing pressure in US generics; (2) TEVA's meaningful debt and inability to de-lever in a timely manner; and (3) high likelihood of Copaxone 40mg generics in 2018."
"We think Mr. Schultz's experience leading financial and restructuring initiatives at global pharmaceutical and healthcare companies could help unlock value for TEVA shares," wrote Cantor Fitzgerald & Co. analyst Louise Chen in a note on Monday, Sept. 11.
Oppenheimer & Co. Inc. analyst Derek Archila wrote that while he views the news positively, Schultz "will be entering the company at a turbulent time, given: (1) continued pricing pressure in US generics; (2) TEVA's meaningful debt and inability to de-lever in a timely manner; and (3) high likelihood of Copaxone 40mg generics in 2018."